Chemical structure of aztreonam
Find information on thousands of medical conditions and prescription drugs.

Aztreonam

Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is useful against gram-negative bacterial pathogens. It is not used to treat colds, viral or flu infections.

It has no useful activity against gram-positive bacteria or anaerobes, but has very broad spectrum against gram-negative aerobes, including Pseudomonas aeruginosa.

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Extended-spectrum [beta]-lactamase-producing flora in healthy persons
From Emerging Infectious Diseases, 6/1/05 by Camilla Rodrigues

To the Editor: Extended-spectrum [beta]-lactamase (ESBL) producing gram-negative bacilli are endemic in hospitals. In intensive care units, 2% prevalence of ESBL-producing organisms has been reported (1). Exceedingly high rates of ESBL-producing bacteria in Indian hospitals prompted us to look at the fecal carriage of ESBL in the community (2).

One hundred healthy executives received a comprehensive health check at our tertiary care center in central Mumbai from August to September 2004. The predominant isolates from stool samples obtained for routine examination were cultured, and initial screening for ESBL production was conducted by using the disk diffusion method according to NCCLS guidelines (3). For these isolates, the ESBL phenotypic confirmation was performed with ceftazidime-clavulanate for an increase in zone diameter by 5 mm (disk potentiation). In addition, the ATB BLSE strip (bioMerieux, Lyon, France) was used to confirm the presence of inhibitor (sulbactam)-susceptible enzymes and to differentiate the strains from those that were either inhibitor resistant or harboring other [beta]-lactamases, such as those of AmpC derivation. The ATB BLSE strip consists of a varying concentration of ceftazidime, 0.5-32 mg/L, and aztreonam, 0.5-8 mg/L, with varying combinations of these agents with a [beta]-lactamase inhibitor, i.e., + sulbactam, 0.06-1 mg/L. Cefotetan (4 and 32 mg/L) and imipenem (4 and 8 mg/L) were also included in the strip. The test was considered positive when a variation of [greater than or equal to] 4 dilutions was observed between the antimicrobial agent tested alone and the agent combined with the inhibitor. Eleven of the 100 samples screened were positive for ESBL-producing Escherichia coli and Klebsiella pneumoniae. Seven of the 11 were confirmed by using the ATB BLSE strip. The MIC of ceftazidime and aztreonam in all 7 isolates was 8 [micro]g/mL. We might be underreporting ESBL producers in these cases by not including the cefotaxime-clavulanate combination in addition to the ceftazidime-clavulanate concentration. The percentage resistance to ciprofloxacin was 45%. All isolates were susceptible to amikacin and the carbapenems. None of the executives gave a history of hospitalization in the last year or history of antimicrobial drug consumption in the last 6 months.

This trend in patients with no apparent risk factors for ESBL carriage calls for urgent attention. Unknown environmental factors are likely playing a key role in maintaining this selective pressure. Larger studies are required to substantiate these findings.

References

(1.) Harris AD, Nemoy L, Johnson J, Carnahan M, Smith DJ, Standiford H, et al. Co-carriage rates of vancomycin resistant Enterococcus and extended spectrum [beta]-lactamases-producing bacteria among a cohort of intensive care unit patients--implications for an active surveillance program. Infect Control Hosp Epidemiol. 2004;25:105-8.

(2.) India Antimicrobial Resistance Study Group, Mathai D, Biendenbach DJ, Jones RN. Evaluation of the in vitro activity of six broad spectrum [beta]-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis. 2002;44:367-77.

(3.) National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th Informational Supplement; M100-S12 Wayne (PA): The Committee; 2002. p. 46.

Camilla Rodrigues, * Upasana Shukla, * Simantini Jog, * and Ajita Mehta *

* P.D. Hinduja National Hospital and Medicine Research Centre, Mumbai, India

Address for correspondence: Camilla Rodrigues, Consultant Microbiologist, RD. Hinduja National Hospital and Medicine Research Centre, Mumbai, India 400016: fax: 91-22-2444-2318: email: dr_crodrigues@ hindujahospital.com

COPYRIGHT 2005 U.S. National Center for Infectious Diseases
COPYRIGHT 2005 Gale Group

Return to Aztreonam
Home Contact Resources Exchange Links ebay